🇺🇸 FDA

Company profile · Sponsor

Madrigal

Madrigal Pharmaceuticals EU Limited

MDGL · NYSE pharma WEST CONSHOHOCKEN, PA, GB
Pipeline
16
Drugs
1
Patents
8

Quick answer

Madrigal (MDGL) is a pharma company. headquartered in WEST CONSHOHOCKEN, PA, GB. listed on NYSE. NovaPharmaNews links 16 pipeline programs, 1 drug, and 8 patents to this profile..

Company facts

Ticker MDGL
Exchange NYSE
Company type pharma
Headquarters WEST CONSHOHOCKEN, PA, GB
SEC CIK 0001157601

Pipeline (16)

Search pipeline →

  1. MGL-3196

    Madrigal

    NASH - Nonalcoholic Steatohepatitis

    phase 3 small molecule active

    1 trial

  2. MGL-3196 80 mg oral, Matching placebo MGL-3196 80 mg film-coated tablet, Matching placebo MGL-3196 60 mg film-coated tablet, MGL-3196 60 mg oral, MGL-3196 100 mg oral, Matching placebo MGL-3196 100 mg film-coated tablet

    Madrigal

    Non-alcoholic Steatohepatitis (NASH) Cirrhosis

    phase 3 small molecule active

    1 trial

  3. Matching placebo MGL-3196 60 mg film-coated tablet, Matching placebo MGL-3196 80 mg film-coated tablet, Matching placebo MGL-3196 100 mg film-coated tablet., MGL-3196 60 mg oral, MGL-3196 100 mg oral, MGL-3196 80 mg oral

    Madrigal

    Non-Alcoholic Steatohepatitis (NASH)

    phase 3 small molecule active

    1 trial

  4. Placebo

    Madrigal

    Non-Alcoholic Fatty Liver Disease

    phase 3 small molecule completed

    1 trial

  5. Resmetirom

    Madrigal

    NASH

    phase 3 small molecule active

    1 trial

  6. Resmetirom

    Madrigal

    Non-Alcoholic Fatty Liver Disease

    phase 3 small molecule active

    1 trial

  7. MGL-3196

    Madrigal

    Non-alcoholic Steatohepatitis

    phase 2 small molecule completed

    1 trial

  8. MGL-3196 (resmetirom)

    Madrigal

    Heterozygous Familial Hypercholesterolemia

    phase 2 small molecule completed

    1 trial

  9. Resmetirom

    Madrigal

    MASH - Metabolic Dysfunction-Associated Steatohepatitis

    phase 2 small molecule active

    1 trial

  10. 100 mg Resmetirom Tablet

    Madrigal

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  11. Atorvastatin

    Madrigal

    Healthy

    phase 1 small molecule completed

    1 trial

  12. MGL-3196

    Madrigal

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  13. MGL-3196

    Madrigal

    Healthy

    phase 1 small molecule completed

    3 trials

  14. MGL-3196 Tablet

    Madrigal

    Healthy

    phase 1 small molecule completed

    1 trial

  15. Placebo

    Madrigal

    Drug Safety

    phase 1 small molecule completed

    2 trials

  16. Simvastatin

    Madrigal

    Healthy

    phase 1 small molecule completed

    1 trial

Drugs (1)

Search drugs →

  1. resmetirom

    REZDIFFRA

    ORAL approved

    A05

Patents (8)

Search patents →

  1. US 12377104

    Methods for treating a fatty liver disease

    Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11986481

    Method of synthesizing thyroid hormone analogs and polymorphs thereof

    Expires Mon May 16 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11806353

    Methods of treating liver disorders or lipid disorders with a THR-beta agonist

    Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11564926

    Methods of synthesizing thyroid hormone analogs and polymorphs thereof

    Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11491145

    Combination therapies comprising targeted therapeutics

    Expires Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11377447

    Targeted therapeutics

    Expires Mon Jun 30 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11090308

    Methods of treating liver disorders or lipid disorders with a THR-beta agonist

    Expires Mon Aug 12 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10894050

    Methods of synthesizing thyroid hormone analogs and polymorphs thereof

    Expires Mon Jan 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Madrigal?

Madrigal (MDGL) is a pharma company. headquartered in WEST CONSHOHOCKEN, PA, GB. listed on NYSE. NovaPharmaNews links 16 pipeline programs, 1 drug, and 8 patents to this profile..

What pipeline programs does Madrigal sponsor?

We track 16 ClinicalTrials.gov-linked programs for Madrigal, including MGL-3196 and 15 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Madrigal company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.